Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Tavros Therapeutics, Inc., a precision oncology platform company, today announced that the Company has achieved two milestone payments in its...

Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform Partnership streamlines drug development for novel cancer therapies ...

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term Vividion will have rights to opt-in to up to five more...

Tavros Therapeutics Raises $7.5 Million in Oversubscribed Seed II Round DURHAM, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tavros Therapeutics, a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities,...